AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10419911 — intervention group
Group type: COMPARATOR
Intervention: Gastroenterologists
Number of subjects: 328
Study 10419911 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 328
Study 7587260 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of preoperative, intraoperative, and postoperative variables (including Parsonnet score, APACHE II and III scores)
Number of subjects: 1008
Study 7587260 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model including bypass time, need for inotropes, mean arterial pressure, urea, and Glasgow Coma Scale
Number of subjects: 1008
Study 7587260 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsonnet score
Number of subjects: 1008
Study 7587260 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II risk of dying
Number of subjects: 1008
Study 1775733 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 6
Study 1775733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen 0.5 mg
Number of subjects: 6
Study 1775733 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline 6 mg
Number of subjects: 6
Study 1775733 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide 2 mg
Number of subjects: 6
Study 1775733 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide alone
Number of subjects: 6
Study 6133757 — intervention group
Group type: COMPARATOR
Intervention: 0.6 mg LH-RH daily for 4 weeks (placebo-controlled)
Number of subjects: 50
Study 6133757 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg LH-RH daily for 4 weeks (open study)
Number of subjects: 50
Study 31349092 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training (IG)
Number of subjects: 32
Study 31349092 — intervention group
Group type: COMPARATOR
Intervention: Conventional eccentric training (CG)
Number of subjects: 32
Study 31349092 — intervention group
Group type: COMPARATOR
Intervention: Single leg hop test
Number of subjects: 32
Study 28233071 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser group (ALG) received pulsed high-intensity laser therapy (HILT) three times per week for 6 weeks, along with 10 mg cetirizine tablets twice daily and 10 mg at bedtime.
Number of subjects: 49
Study 28233071 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser group (ALG) received HILT and cetirizine.
Number of subjects: 49
Study 28233071 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser group (PLG) received placebo HILT and cetirizine.
Number of subjects: 49
Study 26480969 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher glycemic index (GI)
Number of subjects: 6606
Study 26480969 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher glycemic load (GL)
Number of subjects: 6606
Study 26480969 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in dietary GI
Number of subjects: 6606
Study 26480969 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in dietary GL
Number of subjects: 6606
Study 23571799 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical sternum lifting system (ESLS)
Number of subjects: 0
Study 23571799 — intervention group
Group type: COMPARATOR
Intervention: Mechanical sternum lifting device
Number of subjects: 0
Study 21233475 — intervention group
Group type: EXPERIMENTAL
Intervention: HDP cohort
Number of subjects: 1092
Study 21233475 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm delivery in HDP cohort
Number of subjects: 1092
Study 21233475 — intervention group
Group type: EXPERIMENTAL
Intervention: HDP cohort aged 15 to 18 years
Number of subjects: 1092
Study 21233475 — intervention group
Group type: EXPERIMENTAL
Intervention: HDP cohort aged 35 years and older
Number of subjects: 1092
Study 21233475 — intervention group
Group type: COMPARATOR
Intervention: Non-HDP cohort
Number of subjects: 1092
Study 19297566 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening offered at an average of once every 4 years
Number of subjects: 182000
Study 19297566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PSA screening)
Number of subjects: 182000
Study 19297566 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 182000
Study 19297566 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening (actual screened men)
Number of subjects: 182000
Study 17577323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis-containing lozenges
Number of subjects: 29
Study 15631350 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative treatment (n = 31)
Number of subjects: 64
Study 15631350 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (n = 33)
Number of subjects: 64
Study 15631350 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 64
Study 11294772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (10 microg/kg, intravenous bolus)
Number of subjects: 6
Study 11294772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9542481 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen (1000 mg)
Number of subjects: 18
Study 9542481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7760586 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (5 mg twice-daily for 1 month, then 5 mg once-daily for 2 months)
Number of subjects: 42
Study 7760586 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching capsule)
Number of subjects: 42
Study 3417354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ty21a
Number of subjects: 30
Study 3417354 — intervention group
Group type: COMPARATOR
Intervention: TAB
Number of subjects: 30
Study 30998929 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook advertisements designed to increase knowledge of the efficacy, ease of use and safety of LARC
Number of subjects: 152743
Study 30998929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no advertisements)
Number of subjects: 152743
Study 30998929 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook advertisements
Number of subjects: 152743
Study 28049964 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment (NSPT)
Number of subjects: 62
Study 28049964 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 62
Study 26666301 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic early integration of palliative care in standard oncology care
Number of subjects: 182
Study 26666301 — intervention group
Group type: COMPARATOR
Intervention: Standard oncology care alone
Number of subjects: 182
Study 23669294 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg intravenous infusion per year)
Number of subjects: 483
Study 23669294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 21985895 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste M (containing stannous fluoride)
Number of subjects: 12
Study 21985895 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste PE (containing stannous fluoride)
Number of subjects: 12
Study 21985895 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste (containing sodium fluoride)
Number of subjects: 12
Study 18505546 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute submaximal exercise
Number of subjects: 0
Study 18505546 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0
Study 18505546 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive patients
Number of subjects: 0
Study 18505546 — intervention group
Group type: COMPARATOR
Intervention: Patients with CAD
Number of subjects: 0
Study 16406221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microg four times with 4 h intervals)
Number of subjects: 100
Study 16406221 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion (starting from 2 mIU/min, increased every 30 min up to 40 mIU/min)
Number of subjects: 100
Study 16406221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 100
Study 16406221 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 100
Study 12553389 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine 8 mg kg(‐1)
Number of subjects: 80
Study 12553389 — intervention group
Group type: COMPARATOR
Intervention: Oral ketamine 4 mg kg(‐1)
Number of subjects: 80
Study 12553389 — intervention group
Group type: COMPARATOR
Intervention: Oral ketamine 6 mg kg(‐1)
Number of subjects: 80
Study 10845311 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 347
Study 10845311 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 347
Study 8648018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 8648018 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0
Study 8648018 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study 1739573 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium suppositories 150‐200 mg day‐1
Number of subjects: 40
Study 1739573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6746191 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-reduced diet (1370 kcal, 5.7 MJ) with 24 energy per cent carbohydrates
Number of subjects: 23
Study 6746191 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric diet (1400 kcal, 5.8 MJ) with 59 energy per cent carbohydrates (mainly mono- and disaccharides)
Number of subjects: 23
Study 6746191 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Gp I and Gp II)
Number of subjects: 23
Study 31536786 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) denervation and an exercise programme
Number of subjects: 1148
Study 27689315 — intervention group
Group type: EXPERIMENTAL
Intervention: First You Should Get Stronger program
Number of subjects: 40
Study 27421884 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ intervention for 6 months
Number of subjects: 190
Study 27421884 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group for 6 months
Number of subjects: 190
Study 27421884 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ intervention
Number of subjects: 190
Study 27421884 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 190
Study 24740822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular sprifermin (10 μg, 30 μg, 100 μg)
Number of subjects: 192
Study 24740822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 22677328 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical procedure
Number of subjects: 71
Study 22677328 — intervention group
Group type: COMPARATOR
Intervention: Closed surgical procedure
Number of subjects: 71
Study 20586935 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine
Number of subjects: 71
Study 20586935 — intervention group
Group type: COMPARATOR
Intervention: Control (no virological response)
Number of subjects: 71
Study 20586935 — intervention group
Group type: EXPERIMENTAL
Intervention: interferon‐alpha2b
Number of subjects: 71
Study 20586935 — intervention group
Group type: EXPERIMENTAL
Intervention: sequential therapy of lamivudine‐interferon‐alpha2b
Number of subjects: 71
Study 17573292 — intervention group
Group type: EXPERIMENTAL
Intervention: Techniques to enhance recruitment and retention in RCTs for cancer symptom management
Number of subjects: 0
Study 15817970 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 15817970 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin polymer (Haemaccel)
Number of subjects: 60
Study 12368674 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training (MIST VR simulator diathermy task)
Number of subjects: 16
Study 12368674 — intervention group
Group type: COMPARATOR
Intervention: Non‐VR training
Number of subjects: 16
Study 9672727 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cognitive-Behavioural Therapy (MCBT)
Number of subjects: 32
Study 9672727 — intervention group
Group type: COMPARATOR
Intervention: Conjoint Family Therapy (FT)
Number of subjects: 32
Study 9672727 — intervention group
Group type: COMPARATOR
Intervention: Eclectic Therapy (ET)
Number of subjects: 32
Study 8026119 — intervention group
Group type: EXPERIMENTAL
Intervention: AN‐69 dialyzer
Number of subjects: 12
Study 8026119 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone dialyzer
Number of subjects: 12
Study 8026119 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Number of subjects: 12
Study 8026119 — intervention group
Group type: COMPARATOR
Intervention: No ACE inhibitor
Number of subjects: 12
Study 2684661 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate in propylene glycol (n = 20)
Number of subjects: 40
Study 2684661 — intervention group
Group type: COMPARATOR
Intervention: Etomidate in ethanol (n = 20)
Number of subjects: 40
Study 2684661 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 1037229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl apovincaminate (Cavinton)
Number of subjects: 143
Study 1037229 — intervention group
Group type: COMPARATOR
Intervention: Xantinol nicotinate
Number of subjects: 143
Study 30866128 — intervention group
Group type: EXPERIMENTAL
Intervention: Persian translation of work ability index (WAI) questionnaire
Number of subjects: 750
Study 27825957 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml water
Number of subjects: 156
Study 27825957 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 ml water
Number of subjects: 156
Study 27825957 — intervention group
Group type: COMPARATOR
Intervention: No water
Number of subjects: 156
Study 26605084 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom monitoring and peak flow training with feedback
Number of subjects: 227
Study 26605084 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak flow training without feedback
Number of subjects: 227
Study 26605084 — intervention group
Group type: COMPARATOR
Intervention: No peak flow training
Number of subjects: 227
Study 26605084 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal detection training with feedback
Number of subjects: 227
Study 26605084 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal detection training without feedback
Number of subjects: 227
Study 26605084 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 227
Study 26605084 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall symptom perception interventions
Number of subjects: 227
Study 23564595 — intervention group
Group type: EXPERIMENTAL
Intervention: 74 g Corinthian raisins
Number of subjects: 30
Study 23564595 — intervention group
Group type: COMPARATOR
Intervention: 50 g glucose (reference food)
Number of subjects: 30
Study 21775755 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) 600 mg once daily
Number of subjects: 460
Study 21775755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 19857148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole for primary prophylaxis in autologous HSCT recipients
Number of subjects: 0
Study 19857148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole for primary prophylaxis in low-risk allogeneic HSCT recipients
Number of subjects: 0
Study 19857148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mould-active agent for high-risk allogeneic HSCT recipients
Number of subjects: 0
Study 17030231 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg) with fluticasone propionate (100 microg) administered twice daily for 12 weeks
Number of subjects: 183
Study 17030231 — intervention group
Group type: COMPARATOR
Intervention: Montelukast administered daily for 12 weeks
Number of subjects: 183
Study 12614193 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day
Number of subjects: 946
Study 12614193 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg t.i.d.
Number of subjects: 946
Study 12614193 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 946
Study 12614193 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 946
Study 10828632 — intervention group
Group type: EXPERIMENTAL
Intervention: Petrolatum-based formulation delivered via a novel diaper
Number of subjects: 0
Study 10828632 — intervention group
Group type: COMPARATOR
Intervention: Control diaper (identical to test product without petrolatum formulation)
Number of subjects: 0
Study 9124167 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (interval bicycle ergometer and treadmill walking training exercises)
Number of subjects: 18
Study 9124167 — intervention group
Group type: COMPARATOR
Intervention: Activity restriction
Number of subjects: 18
Study 9124167 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 18
Study 8400729 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical zona pellucida thinning (experimental group, n = 110)
Number of subjects: 218
Study 8400729 — intervention group
Group type: COMPARATOR
Intervention: Control group (unmanipulated embryos, n = 108)
Number of subjects: 218
Study 8400729 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical zona thinning applied to embryos with less than 4.0 microns variation in zona thickness
Number of subjects: 218
Study 2876485 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (1 mg h.s.)
Number of subjects: 10
Study 2876485 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg h.s.)
Number of subjects: 10
Study 31828166 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted insulin (daily insulin needed on the day after hemodialysis)
Number of subjects: 51
Study 31828166 — intervention group
Group type: COMPARATOR
Intervention: Nonadjusted insulin (25% decrease in daily insulin needed on the day after hemodialysis)
Number of subjects: 51
Study 30591697 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (10% reduction over six months) in group II (decreased AIP)
Number of subjects: 52
Study 30591697 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (10% reduction over six months) in group I (increased AIP)
Number of subjects: 52
Study 26437376 — intervention group
Group type: EXPERIMENTAL
Intervention: ITX5061 (150 mg immediately before and after transplant and daily for 1 week)
Number of subjects: 23
Study 26437376 — intervention group
Group type: COMPARATOR
Intervention: Control (first 13 patients did not receive drug)
Number of subjects: 23
Study 26437376 — intervention group
Group type: EXPERIMENTAL
Intervention: ITX5061
Number of subjects: 23
Study 26437376 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study 25142566 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 54
Study 25142566 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy for insomnia (MBTI)
Number of subjects: 54
Study 25142566 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring (SM)
Number of subjects: 54
Study 22052061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis
Number of subjects: 0
Study 19488642 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 3
Study 19488642 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3
Study 19488642 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination hydralazine/nitrate
Number of subjects: 3
Study 17250745 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of physostigmine
Number of subjects: 100
Study 17250745 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 100
Study 15774291 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine granules (0.5 g/kg per day for 14 days)
Number of subjects: 48
Study 15774291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine)
Number of subjects: 48
Study 12081987 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat 80 mg daily
Number of subjects: 167
Study 12081987 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 40 mg daily
Number of subjects: 167
Study 9810809 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation
Number of subjects: 0
Study 9810809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7656295 — intervention group
Group type: EXPERIMENTAL
Intervention: Water rinsing after brushing
Number of subjects: 4294
Study 7656295 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing twice a day
Number of subjects: 4294
Study 7656295 — intervention group
Group type: COMPARATOR
Intervention: Baseline examination
Number of subjects: 4294
Study 7656295 — intervention group
Group type: COMPARATOR
Intervention: Year 1 examination
Number of subjects: 4294
Study 7656295 — intervention group
Group type: COMPARATOR
Intervention: Year 2 examination
Number of subjects: 4294
Study 7656295 — intervention group
Group type: COMPARATOR
Intervention: Year 3 examination
Number of subjects: 4294
Study 7656295 — intervention group
Group type: COMPARATOR
Intervention: Restorations at baseline
Number of subjects: 4294
Study 7656295 — intervention group
Group type: COMPARATOR
Intervention: Restorations at Year 1
Number of subjects: 4294
Study 7656295 — intervention group
Group type: COMPARATOR
Intervention: Restorations at Year 2
Number of subjects: 4294
Study 7656295 — intervention group
Group type: COMPARATOR
Intervention: Restorations at Year 3
Number of subjects: 4294
Study 2697708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine, sulphadiazine and corticosteroids (n = 29)
Number of subjects: 106
Study 2697708 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin, sulphadiazine and corticosteroids (n = 37)
Number of subjects: 106
Study 2697708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (trimethoprim and sulphamethoxazole) and corticosteroids (n = 8)
Number of subjects: 106
Study 2697708 — intervention group
Group type: COMPARATOR
Intervention: No systemic therapy (group 4, n = 32)
Number of subjects: 106
Study 180196 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with 3% adenine arabinoside
Number of subjects: 63
Study 180196 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment with placebo ointment
Number of subjects: 63